Trials / Completed
CompletedNCT06277765
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | Interleukin-4 receptor(IL-4Rα) monoclonal antibody |
| OTHER | placebo | Placebo |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2025-01-23
- Completion
- 2025-01-23
- First posted
- 2024-02-26
- Last updated
- 2025-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06277765. Inclusion in this directory is not an endorsement.